Windmill Cardiovascular Systems

Executive Summary

Windmill Cardiovascular Systems is a private medical device company based in Austin, Texas, founded in 2015. The company is developing the TORVAD, a novel, fully implantable toroidal ventricular assist device (VAD) designed for patients with advanced heart failure. Unlike traditional axial or centrifugal VADs, the TORVAD utilizes a toroidal pumping mechanism that provides gentle blood handling and synchronous, pulsatile flow, closely mimicking natural heart function. This design aims to reduce complications such as hemolysis, thrombosis, and gastrointestinal bleeding, which are common with current continuous-flow VADs. The TORVAD represents a potential paradigm shift in mechanical circulatory support, offering improved hemodynamic performance and patient quality of life. The company is currently in the preclinical or early clinical stage, with a focus on obtaining regulatory approvals and initiating human studies. While specific financial details are undisclosed, Windmill has likely raised seed or Series A funding to support its development efforts. The company's innovative approach addresses a significant unmet need in the heart failure market, which is growing due to an aging population and limited donor hearts for transplantation.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval for First-in-Human Feasibility Study65% success
• Q4 2026Presentation of Preclinical or Early Clinical Data at Major Cardiology Conference70% success
• TBDAnnouncement of Series B or Strategic Partnership50% success